Provexis seeks long-term alliance with DSM Nutritional for Fruitflow product

Provexis PLC (AIM: PSX) said it has entered into a Letter of Intent for its Fruitflow technology with DSM Nutritional Products with a view to establish a long-term alliance giving DSM exclusive global rights to the water-soluble tomato concentrate.

Provexis discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies. DSM Nutritional Products supplies vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries.

The planned agreement will provide for a partnership and structure in which DSM and Provexis will develop, market and sell Fruitflow as an ingredient in all formats and territories. Profits will be shared by the parties on an agreed basis, linked to various performance milestones.

Provexis will continue to support the development of current and future formats of Fruitflow and DSM will contribute with its manufacturing and selling experience and excellence to a successful commercialisation of Fruitflow.

Provexis calls the development of water-soluble tomato concentrate Fruitflow a breakthrough in anti-thrombotic food technology.  In human trials, consumption of the Fruitflow extract has been proven to reduce platelet aggregation in 97 percent of subjects. The effect takes place within three hours of consumption and lasts for up to eighteen hours, making it ideal for daily dosage in functional foods or dietary supplements.  Provexis has developed a syrup format for use in food and beverages and a concentrated powder format for tablets and capsules.

Fruitflow syrup has been given GRAS status (Generally Regarded as Safe) by the US FDA and is not regarded as a Novel Food in the EU, clearing it for wide use in foods, beverages and supplements. In May 2009, the Fruitflow technology was the first to be substantiated by the European Food Safety Authority (EFSA) under a new Article 13(5) for proprietary and emerging science. In December 2009 the European Commission authorised the health claim "Helps maintain normal platelet aggregation, which contributes to healthy blood flow” under the Article.

The technology has been granted patents in the EU, US, Australia, Canada and Mexico, with Japan pending. Further patents have been filed for the bioactive components of Fruitflow and for other developmental areas such as deep vein thrombosis and triglyceride lowering. 

http://www.proactiveinvestors.co.uk/companies/news/13236/provexis-seeks-long-term-alliance-with-dsm-nutritional-for-fruitflow-product-13236.html